Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Hard Copy CD ROM Electronic (PDF) Site License Enterprisewide Launching Pharmaceutical Megabrands: Best Practices in Marketing Blockbusters Best Practices LLC, July 2004, Pages: 169   Description     Table of Contents     Summary     Companies Mentioned        Enquire before Buying    Send to a Friend   Launching Pharmaceutical Megabrands: Best Practices in Marketing Blockbusters (SM-124) profiles an elite group of high performing pharmaceutical companies that have demonstrated effective operating practices and winning strategies in the area of Marketing Pharmaceutical Blockbusters. By studying other organizations’ successful approaches to marketing blockbusters, your company can improve its multi-phased pre-launch marketing support to drive rapid uptake of new products. After reading this report, you will know how world-class pharmaceutical companies drive commercially focused drug development to create blockbuster megabrands. Benefits of commercially focused drug development include increased sales, increased speed to market penetration, improved product positioning and market acceptance, and greater marketing impact through market assessment and preparation activities. This online report summary includes key findings, report structure, sample best practices, a table of contents, project maps that illustrate the study's focus, and an order form to facilitate purchase. METRICS INCLUDED IN THE STUDY Performance metrics enable executives to perform gap analyses and identify areas needing improvement. Metrics are an important complement to the qualitative best practices included in this study report. Best Practices, LLC analysts collected and analyzed the following key metrics for blockbuster product launches from the companies benchmarked in the study: - Marketing activities and frequencies at each product phase - Pre-launch marketing investments - Total marketing spend for global and U.S. operations - Pre-launch vs. launch marketing spend - Marketing spend by activity - New drug marketing investment by company, phase and activity - Composition and size of product teams - Marketing compensation levels - Product/Brand manager qualifications - Marketing publications staff responsibilities Product samples Launching Pharmaceutical Megabrands - Brochure Customers who bought this item also bought European Pharmaceutical Marketing: Launching Successful Brands Pharmaceutical Sales Training: Turning New Hires into Top Performers Pharmaceutical Licensing Strategies: Best Practices in Deal-Making, Valuations and Strategic Management Marketing Mid-Tier Pharmaceutical Brands: Winning Resources for Near-Blockbusters Winning Pharmaceutical Brand Management: Maximizing Brand Value through Best Practice in Brand Development and Product Marketing The Prescribing Data Restriction Program: Critical Assessment and Best Practices Blockbuster Drugs: A 2005-2014 Forecast Otsuka Pharmaceutical Co Deals Briefing

		Top of page

All rights reserved. � Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster